Patents by Inventor Takeshi Tomonaga

Takeshi Tomonaga has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7611855
    Abstract: Using two types of antibodies, i.e., a first antibody having a higher affinity for a target substance than for a competitive substance and a second antibody having a higher affinity for the competitive substance than for the target substance, a specimen is treated with these two antibodies. Then, the competitive substance in the specimen first binds to the second antibody and thus the ratio of the target substance to the competitive substance in the specimen is enlarged. As a result, the target substance becomes liable to bind to the first antibody and, in its turn, the reactivity of the target substance is elevated compared with the case of using the first antibody alone. Thus, the target substance in the specimen can be accurately assayed while avoiding the effects of the competitive substance contained in the specimen.
    Type: Grant
    Filed: December 24, 2003
    Date of Patent: November 3, 2009
    Assignee: Nitto Boseki Co., Ltd.
    Inventors: Tatsuya Ohashi, Toshihide Miura, Yoshihiko Igarashi, Fumio Nomura, Takeshi Tomonaga, Katsuhiro Katayama
  • Patent number: 7517951
    Abstract: Using the protein chip technology, biological samples such as sera are subjected to proteome analysis. Thus, a protein which is a human fibrinogen ?-E chain decomposition product and has a molecular weight of 5,900, a protein which is an apolipoprotein AII decomposition product and has a molecular weight of 7,800, and a protein which is an apolipoprotein AI decomposition product and has a molecular weight of 28,000, each showing an increase or a decrease with the habit of drinking, are newly found out. By detecting or quantifying these proteins, a liver disease in a subject such as one having a problem of drinking can be diagnosed at the early stage.
    Type: Grant
    Filed: December 24, 2003
    Date of Patent: April 14, 2009
    Assignee: Nitto Boseki Co., Ltd.
    Inventors: Fumio Nomura, Kazuyuki Sogawa, Takeshi Tomonaga, Takenori Ochiai, Hideaki Shimada, Tatsuya Ohashi, Katsuhiro Katayama
  • Publication number: 20080227705
    Abstract: An object of the present invention is to provide a novel means for stably and surely inducing cell apoptosis using the c-myc gene as a target. The present invention relates to an apoptosis-inducing agent containing a protein that interacts with an FBP protein or a polynucleotide encoding the protein as an active ingredient and a method for inducing apoptosis, which comprises a step of causing the apoptosis-inducing agent to come into contact with cells.
    Type: Application
    Filed: January 25, 2008
    Publication date: September 18, 2008
    Applicant: Japan Science and Technology Agency
    Inventors: Hideaki Shimada, Kazuyuki Matsushita, Takeshi Tomonaga, Fumio Nomura, Takenori Ochiai
  • Publication number: 20080219981
    Abstract: The present invention provides novel solid cancer antigenic proteins, and diagnostic kits for solid cancer and therapeutic agents for solid cancer based on the antigenic proteins. Specifically, the present invention provides a human solid cancer antigenic polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 48, 50, 52, 54, 56, 59, 61, 63, 65, 67, 69, 71, 73, and 75.
    Type: Application
    Filed: March 24, 2005
    Publication date: September 11, 2008
    Inventors: Hideki Shimada, Takeshi Tomonaga, Takaki Hiwasa, Kazuyuki Matsushita, Takenori Ochiai, Fumio Nomura, Masaki Takiguchi
  • Publication number: 20060199946
    Abstract: An object of the present invention is to provide a novel means for stably and surely inducing cell apoptosis using the c-myc gene as a target. The present invention relates to an apoptosis-inducing agent containing a protein that interacts with an FBP protein or a polynucleotide encoding the protein as an active ingredient and a method for inducing apoptosis, which comprises a step of causing the apoptosis-inducing agent to come into contact with cells.
    Type: Application
    Filed: March 30, 2004
    Publication date: September 7, 2006
    Inventors: Hideaki Shimada, Kazuyuki Matsushita, Takeshi Tomonaga, Fumio Nomura, Takenori Ochiai
  • Publication number: 20060116504
    Abstract: Using the protein chip technology, biological samples such as sera are subjected to proteome analysis. Thus, a protein which is a human fibrinogen ?-E chain decomposition product and has a molecular weight of 5,900, a protein which is an apolipoprotein AII decomposition product and has a molecular weight of 7,800, and a protein which is an apolipoprotein AI decomposition product and has a molecular weight of 28,000, each showing an increase or a decrease with the habit of drinking, are newly found out. By detecting or quantifying these proteins, a liver disease in a subject such as one having a problem of drinking can be diagnosed at the early stage.
    Type: Application
    Filed: December 24, 2003
    Publication date: June 1, 2006
    Applicant: Nitto Boseki Co., Ltd.
    Inventors: Fumio Nomura, Kazuyuki Sogawa, Takeshi Tomonaga, Takenori Ochiai, Hideaki Shimada, Tatsuya Oshashi, Katsuhiro Katayama